Bio-Techne Corp EBITDA 2010-2025 | TECH

Bio-Techne Corp EBITDA for the quarter ending June 30, 2025 was $0.003B, a 95.6% decline year-over-year.

  • Bio-Techne Corp 2025 EBITDA was 0.212B, a 33.37% decline from 2024.
  • Bio-Techne Corp 2024 EBITDA was 0.318B, a 21.61% decline from 2023.
  • Bio-Techne Corp 2023 EBITDA was 0.406B, a 2.14% increase from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Bio-Techne Corp EBITDA 2010-2025 | TECH

  • Bio-Techne Corp 2025 EBITDA was 0.212B, a 33.37% decline from 2024.
  • Bio-Techne Corp 2024 EBITDA was 0.318B, a 21.61% decline from 2023.
  • Bio-Techne Corp 2023 EBITDA was 0.406B, a 2.14% increase from 2022.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.1B
Amgen (AMGN)$155.3B
Gilead Sciences (GILD)$141.6B
Vertex Pharmaceuticals (VRTX)$99.7B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.7B
CSL (CSLLY)$67.1B
Regeneron Pharmaceuticals (REGN)$60.7B
Alnylam Pharmaceuticals (ALNY)$58.2B
Argenex SE (ARGX)$41.5B
Insmed (INSM)$27.1B
BioNTech SE (BNTX)$25.3B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$20B
Incyte (INCY)$16.6B
Genmab (GNMSF)$16.2B
Genmab (GMAB)$15.6B
Illumina (ILMN)$15.3B
Ascendis Pharma (ASND)$11.7B
BioMarin Pharmaceutical (BMRN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.9B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$9.9B
Verona Pharma American Depositary Share (VRNA)$9.1B
Exact Sciences (EXAS)$8.6B
Halozyme Therapeutics (HALO)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Guardant Health (GH)$7.7B